Clinical trialNCT06947928RecruitingPhase 2/PHASE3Interventional

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

SponsorTuHURA Biosciences, Inc.Enrollment118Advanced Or Metastatic Merkel Cell Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew S Brohl, MD
Collaborator
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
In Gino, MD
Recruiting
University of California San Francisco - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Adil Daud, MD
Recruiting
Stanford Health Care - Skin Cancer Program
Stanford, California, United States
Sunil Reddy, MD
Recruiting
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado, United States
Theresa Medina, MD
Recruiting
Mayo Clinic Comprehensive Cancer Center
Jacksonville, Florida, United States
Ruqin Chen, MD
Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Lynn Feun, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Andrew Brohl, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Karam Khaddour, MD
Recruiting
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, United States
Tassos Dimou, MD
Recruiting
Hackensack University Medical Center
Hackensack, New Jersey, United States
Andrew Pecora, MD
Recruiting
Atlantic Health System
Morristown, New Jersey, United States
Eric Whitman, MD
Recruiting
East Carolina University
Greenville, North Carolina, United States
Nasreen Vohra, MD
Recruiting
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Melissa Burgess, MD
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Neal Akhave, MD
Recruiting
Inova Schar Cancer
Fairfax, Virginia, United States
Jafar Al-Mondhiry, MD
Recruiting
Virginia Commonwealth University
Richmond, Virginia, United States
Andrew Poklepovic, MD
Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Shailender Bhatia, MD
Recruiting
West Virginia University
Morgantown, West Virginia, United States
Joanna Kolodney, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Dec 2025
Primary completion: 31 Mar 2027
Completion: 30 Dec 2032
Last update posted: 17 Apr 2026
Registered enrollment: 118
Registry id: NCT06947928

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.